Nuclear medicine diagnostics market to reach $13.77B by 2030

The Business Research Company says the nuclear medicine diagnostics market will grow from $7.88 billion in 2025 to $8.84 billion in 2026, then climb to $13.77 billion by 2030. The report points to rising cancer rates, more PET imaging, and expanding theranostics as key drivers of demand.

Why it matters: - Nuclear medicine diagnostics is becoming more important for spotting and monitoring disease, especially cancer. - The market’s expected growth signals rising demand for functional imaging, targeted radiopharmaceuticals and precision oncology tools.

What happened: - The Business Research Company released a report on the global nuclear medicine diagnostics market covering 2026 through 2035. - The market is projected to rise from $7.88 billion in 2025 to $8.84 billion in 2026. - The report forecasts the market will reach $13.77 billion by 2030. - North America held the largest market share in 2025.

The details: - The 2025-to-2026 increase implies 12.2% CAGR. - The 2026-to-2030 forecast implies 11.7% CAGR. - Growth in the historical period is tied to wider use of radioactive tracers, more hospital-based nuclear medicine departments, stronger demand for functional imaging, broad availability of technetium-based radiopharmaceuticals and more clinical research. - Future growth is linked to investment in theranostics, broader precision oncology diagnostics, new PET imaging facilities, targeted radiopharmaceutical development and more regulatory support for nuclear diagnostic technologies. - Key trends include more PET-based diagnostic radiopharmaceuticals, higher demand for personalized nuclear diagnostics, tighter integration of imaging and therapy, more oncology-focused nuclear medicine use and greater emphasis on short-half-life radiotracers. - The report says nuclear medicine uses radioactive substances inside the body to diagnose conditions or treat damaged tissues and organs. - In diagnostics, radioactive tracers help visualize or measure organ function and support diagnosis and treatment planning. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offers a free sample and a full version.

Between the lines: - Cancer remains the clearest demand driver because nuclear medicine is used for detection, staging and monitoring across multiple cancer types. - The report cites National Cancer Institute data showing nearly 20 million cancer diagnoses in 2022 and 9.7 million deaths, with annual cases projected to reach 33 million and deaths 18.2 million by 2050. - That projected rise in cancer burden helps explain why diagnostic imaging tied to oncology is drawing more investment.

What's next: - The market is expected to keep expanding as more health systems adopt PET imaging and targeted diagnostic radiopharmaceuticals. - Broader regulatory support and continued innovation in theranostics could push adoption further over the next several years. - The report’s 2030 forecast suggests the category will remain in a high-growth phase through the end of the decade.

The bottom line: - Nuclear medicine diagnostics is moving from a niche imaging category toward a larger role in cancer care and precision medicine, with growth driven by technology, research and rising disease burden.